Agios Pharmaceuticals

Agios’ moat rests on intangible assets (orphan approvals, patents for mitapivat with Orange Book listings into the late 2030s to early 2040s) and efficient scale in rare hematology, augmented by distribution partnerships in Europe (Avanzanite) and the Gulf (NewBridge).

Patent and exclusivity positions plus first‑in‑class status in multiple settings create barriers to entry, especially in PK deficiency where alternatives are limited.

However, the moat is not impregnable: (1) gene therapies in thalassemia and sickle cell can structurally disrupt demand over time despite access, cost and safety hurdles; (2) a boxed warning and REMS for AQVESME elevate prescriber and payer friction; and (3) sickle cell success still hinges on confirmatory evidence under the accelerated pathway.

Component view (weighting/100): Intangibles 75/35, Efficient scale 70/25, Switching costs 60/20, Cost advantage 50/10, Network effects 10/10. Weighted outcome ≈ mid‑60s given durability of IP/exclusivity but offset by long‑term gene therapy risk and REMS friction.